Head to Head Review: IN8bio (NASDAQ:INAB) vs. Windtree Therapeutics (NASDAQ:WINT)

Windtree Therapeutics (NASDAQ:WINT) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Institutional & Insider Ownership

29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 0.3% of Windtree Therapeutics shares are held by insiders. Comparatively, 15.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Windtree Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500.

Profitability

This table compares Windtree Therapeutics and IN8bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Windtree Therapeutics	N/A	-362.76%	-79.65%
IN8bio	N/A	-197.15%	-130.48%

Analyst Ratings

This is a summary of current ratings and recommmendations for Windtree Therapeutics and IN8bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Windtree Therapeutics	0	1	0	0	2.00
IN8bio	0	0	2	0	3.00

Windtree Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 5,752.84%. IN8bio has a consensus target price of $7.75, suggesting a potential upside of 2,953.59%. Given Windtree Therapeutics’ higher probable upside, equities research analysts plainly believe Windtree Therapeutics is more favorable than IN8bio.

Valuation & Earnings

This table compares Windtree Therapeutics and IN8bio”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Windtree Therapeutics	N/A	N/A	-$20.29 million	($16.47)	-0.01
IN8bio	N/A	N/A	-$30.01 million	($0.75)	-0.34

IN8bio is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

IN8bio beats Windtree Therapeutics on 6 of the 11 factors compared between the two stocks.

About Windtree Therapeutics

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee’s Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

About IN8bio

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.